Live Breaking News & Updates on Ipilimumab

Stay updated with breaking news from Ipilimumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). ....

European-medicines-agency , Bristol-myers-squibb-co , Bristol-myers-squibb , Blinded-independent-clinical-review , Bmy , Metastatic-colorectal-cancer , Bristol-myers-squibb , Ipilimumab , Ervoy- , Nivolumab , Opdivo

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma. ....

Nottingham , United-kingdom , Lindy-durrant , University-of-nottingham , Academic-department-of-clinical-oncology , Academic-department , Clinical-oncology , Scib1 , Nivolumab , Ipilimumab , Melanoma ,

When Does the PD-1 Inhibitor Come Before the Hedgehog Inhibitor for Neoadjuvant BCC/CSCC?

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers. ....

Boston , Massachusetts , United-states , Washington , France , Stanford , California , Florida , Texas , Houston , University-of-california-san-francisco , Vishala-patel

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions. ....

Advanced-renal-cell-carcinoma , Term-follow-up , Renal-cell-carcinoma , Nrcc , Advanced-rcc , Checkmate-214 , Nivolumab , Ipilimumab , Metastatic-clear-cell-rcc , Ctla4-inhibition , Ctla4

First-Line Treatments for Advanced Clear Cell RCC

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC. ....

Advanced-renal-cell-carcinoma , Line-treatments , Advanced-clear-cell , Renal-cell-carcinoma , Nrcc , Advanced-rcc , Clear-cell-renal-carcinoma , Non-clear-cell-renal-carcinoma , Immunotherapy , Ipilimumab , Nivolumab